The demographics of ageing suggest a great need for an early diagnosis of dementia and for the development of preventive strategies. Neurodegeneration in Alzheimers disease is estimated to start 20-30 years before clinical onset, and the identification of biological markers for pre-clinical and early diagnosis is the principal aim of research studies in the field. In this book, the authors present topical research on Alzheimers diagnosis including cerebrospinal fluid biomarker Amyloid-B 1-42 identification; visual impairment in Alzheimers disease; cerebral glucose metabolism through F-fluoro-deoxy-glucose positron emission tomography and neuroimaging.
Preface; Quantitation of Amyloid-ß Oligomers in Human Body Fluids for Alzheimers Disease Early Diagnosis or Therapy Monitoring?; Visual Impairment in Alzheimer Disease:: Clinical, Pathophysiological & Instrumental Aspects; Alzheimers Disease Diagnosis:: A New Approach; Mitochondrial Haplogroups Associated with Japanese Alzheimers Patients; Leading Role & Limits of 18F-FDG-PET Imaging in Early Diagnosis of Alzheimers Disease; Artificial Neural Networks in Alzheimers Diagnosis:: A Perspective; Milestones & Difficulties in Alzheimers Disease Diagnosis; The Role of Neuroimaging in the Early Diagnosis of Alzheimers Disease; Cerebrospinal Fluid Biomarkers for Alzheimers Disease; Index.
Komentarze (0)
Chwilowo nie możesz polubić tej opinii
Zgłoś komentarz
Czy jesteś pewien, że chcesz zgłosić ten komentarz?
Zgłoszenie wysłane
Twój komentarz został wysłany i będzie widoczny po zatwierdzeniu przez moderatora.